{"id":127377,"date":"2026-09-08T05:36:07","date_gmt":"2026-09-08T05:36:07","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/127377\/"},"modified":"2026-09-08T05:36:07","modified_gmt":"2026-09-08T05:36:07","slug":"novartis-enters-into-exclusive-promotion-and-distribution-agreement-with-novartis-healthcare-capital-market-news","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/127377\/","title":{"rendered":"Novartis enters into exclusive promotion and distribution agreement with Novartis Healthcare | Capital Market News"},"content":{"rendered":"<p> Last Updated : Sep 08 2026 | 10:31 AM IST<\/p>\n<p>For distribution of Accentrix? (ranibizumab) and Pagenax? (brolucizumab) in India<\/p>\n<p>Novartis India has entered into an Exclusive Promotion and Distribution Agreement dated 8 September 2026 with Novartis Healthcare (NHPL). <\/p>\n<p>Under the terms of the said Agreement, the Company has been granted the rights to exclusively promote and distribute NHPL&#8217;s retina portfolio comprising the products Accentrix (ranibizumab) and Pagenax (brolucizumab) for the territory of India. <\/p>\n<p>The Agreement is expected to support the Company&#8217;s entry into the ophthalmology therapy area and expand its commercial portfolio.<\/p>\n<p>The upfront consideration payable by the Company to NHPL shall be Rs 10 crore. <\/p>\n<p>\u00a0<\/p>\n<p style=\"font-style: italic;\" id=\"auto_disclaimer\">Disclaimer:  No Business Standard Journalist was involved in creation of this content<\/p>\n<p>First Published: Sep 08 2026 | 10:31 AM IST<\/p>\n","protected":false},"excerpt":{"rendered":"Last Updated : Sep 08 2026 | 10:31 AM IST For distribution of Accentrix? (ranibizumab) and Pagenax? (brolucizumab)&hellip;\n","protected":false},"author":2,"featured_media":127378,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[62189,62191,62188,62190,13183,21379,1360,1002,191,5779,206,10088,9922,35006,8269],"class_list":["post-127377","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-antivascular-endothelial-growth-factor-therapy","tag-biotechnology-medical-research-nec","tag-breakthrough-therapy","tag-calvin-a-grant","tag-cancer-treatments","tag-clinical-medicine","tag-genentech","tag-health","tag-india","tag-medicine","tag-novartis","tag-novartis-healthcare","tag-novartis-india","tag-pharmaceuticals-nec","tag-ranibizumab"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117233803814939047","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/127377","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=127377"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/127377\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/127378"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=127377"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=127377"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=127377"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}